×
About 14,698 results

ALLMedicine™ Non-Hodgkin Lymphoma Center

Research & Reviews  4,345 results

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
https://clinicaltrials.gov/ct2/show/NCT03564470

Jul 1st, 2022 - Ph-like, or BCR-ABL1-like lymphoblastic leukemia is neoplasm of lymphoblasts committed to the B-cell lineage that lack the BCR-ABL1 translocation but show a pattern of the expression very similar to that seen in BCR-ABL1-positive ALL. Chidamide is...

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Ped...
https://clinicaltrials.gov/ct2/show/NCT03526250

Jul 1st, 2022 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymph...

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
https://clinicaltrials.gov/ct2/show/NCT05371054

Jul 1st, 2022 - Background: High unmet medical need for relapsed/refractory non-Hodgkin lymphoma (NHL) after exhausting chemotherapy and/or chemo-immunotherapy regimens Targeted therapies aimed at disrupting cell death pathway in hematologic malignancies are emer...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

Jul 1st, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

see more →

Guidelines  4 results

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Practical recommendations for fertility preservation in women by the FertiPROTEKT netwo...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762797
Archives of Gynecology and Obstetrics; Schüring AN, Fehm T et. al.

Nov 28th, 2017 - Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice. A selective ...

Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.
https://doi.org/10.1016/j.clon.2016.09.004
Clinical Oncology (Royal College of Radiologists (Great B... Prica A, Baldassarre F et. al.

Oct 18th, 2016 - Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aim...

see more →

Drugs  59 results see all →

Clinicaltrials.gov  540 results

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
https://clinicaltrials.gov/ct2/show/NCT03564470

Jul 1st, 2022 - Ph-like, or BCR-ABL1-like lymphoblastic leukemia is neoplasm of lymphoblasts committed to the B-cell lineage that lack the BCR-ABL1 translocation but show a pattern of the expression very similar to that seen in BCR-ABL1-positive ALL. Chidamide is...

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Ped...
https://clinicaltrials.gov/ct2/show/NCT03526250

Jul 1st, 2022 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymph...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

Jul 1st, 2022 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
https://clinicaltrials.gov/ct2/show/NCT00967785

Jul 1st, 2022 - Mozobil (TM) (plerixafor injection, Genzyme/Sanofi) is a Food and Drug Administration approved medication to mobilize CD34+ hematopoietic stem cells prior to apheresis and use in autologous transplantation in non-Hodgkin lymphoma and multiple myel...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

Jul 1st, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas an...

see more →

News  928 results

‘Exciting’ new gene therapy yields promising results
https://www.mdedge.com/hematology-oncology/article/255210/gene-therapy/exciting-new-gene-therapy-yields-promising-results
Heidi Splete

Jun 5th, 2022 - Patients with relapsed or refractory B cell non-Hodgkin lymphoma responded positively to a new therapy based on genome editing in early results from a phase 1 study, according to a news release from manufacturer Caribou Biosciences. In the first-i.

Ublituximab/Umbralisib BLA/sNDA in CLL and SLL Voluntarily Withdrawn
https://www.onclive.com/view/ublituximab-umbralisib-bla-snda-in-cll-and-sll-voluntarily-withdrawn

May 6th, 2022 - The pending biologics license application (BLA) and supplemental new drug application (sNDA) seeking the approval of the combination of ublituximab and umbralisib (Ukoniq; U2) in adult patients with chronic lymphocytic leukemia (CLL) and small lym...

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL
https://www.onclive.com/view/dr-westin-on-the-evolving-landscape-of-car-t-cell-therapy-in-nhl

May 3rd, 2022 - Jason R. Westin, MD, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolv...

Dr. Bezerra on Barriers to Enrollment for Clinical Trials in B-Cell NHL
https://www.onclive.com/view/dr-bezerra-on-barriers-to-enrollment-for-clinical-trials-in-b-cell-nhl

Apr 26th, 2022 - Evandro D. Bezerra, MD, clinical fellow of Hematology, Mayo Clinic, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have progressed on anti-CD19 CAR T-cell therapy. This patie...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

see more →

Patient Education  3 results see all →